Skip to main content
Top
Published in: Journal of Radiation Oncology 3-4/2020

01-12-2020 | Coronavirus | Review

Early detection of SARS-CoV-2 from staging PET-CT

Authors: Mohamed H. Khattab, Alexander D. Sherry, Aaron C. Jessop, Kristen K. Ciombor, Bapsi Chakravarthy

Published in: Journal of Radiation Oncology | Issue 3-4/2020

Login to get access

Abstract

Objective

SARS-CoV-2 infection may manifest with minimal or no clinical symptoms. However, signs of infection may appear on routine imaging obtained in the care of patients with cancer. The management of patients planned for chemoradiation with asymptomatic or mildly symptomatic SARS-CoV-2 infection is uncertain.

Methods

Here, we present a case study of a mildly symptomatic patient with anal cancer diagnosed with SARS-CoV-2 from a staging PET-CT scan.

Results

PET-CT scan for anal cancer staging demonstrated pulmonary avidity suspicious for an infectious, rather than malignant, process. In the setting of these imaging findings and new-onset anosmia, viral polymerase chain reaction was ordered and found to be positive for SARS-CoV-2. To avoid myelosuppression in the setting of active infection, planned chemoradiation was delayed until cessation of viral shedding.

Conclusion

In the COVID-19 era, oncologists obtaining routine staging imaging should have high diagnostic suspicion for subclinical SARS-CoV-2 infection. To avoid precipitating severe pneumonia and hospitalization, multidisciplinary discussion with risk-benefit analysis is recommended before initiating immunosuppressive therapies such as chemoradiation.
Literature
1.
Metadata
Title
Early detection of SARS-CoV-2 from staging PET-CT
Authors
Mohamed H. Khattab
Alexander D. Sherry
Aaron C. Jessop
Kristen K. Ciombor
Bapsi Chakravarthy
Publication date
01-12-2020
Publisher
Springer Berlin Heidelberg
Published in
Journal of Radiation Oncology / Issue 3-4/2020
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-020-00436-w

Other articles of this Issue 3-4/2020

Journal of Radiation Oncology 3-4/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine